Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome

Pediatrics International

Volumn 55, Issue 5, 2013, Pages

  Kawasaki, Yukihiko ^a   Suyama, Kazuhide ^a   Ono, Atsushi ^a   Oikawa, Tomoko ^a   Ohara, Shinichiro ^a   Suzuki, Yuichi ^a   Sakai, Nobuko ^a   Hosoya, Mitsuaki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

hemolytic uremic syndrome; O 157. renal insufficiency; recombinant human soluble thrombomodulin

Indexed keywords

ACETYLGLUCOSAMINIDASE; ANTICOAGULANT AGENT; BETA 2 MICROGLOBULIN; CREATININE; D DIMER; FIBRIN DEGRADATION PRODUCT; LACTATE DEHYDROGENASE; PROTEIN; RECOMBINANT THROMBOMODULIN;

ACUTE KIDNEY FAILURE; ARTICLE; BLOODY DIARRHEA; CASE REPORT; CHILD; CHILDHOOD DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; FEMALE; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; PARTIAL THROMBOPLASTIN TIME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; THROMBOCYTOPENIA;

HEMOLYTIC UREMIC SYNDROME; O-157. RENAL INSUFFICIENCY; RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN;

CHILD, PRESCHOOL; CREATININE; FEMALE; FOLLOW-UP STUDIES; HEMOLYTIC-UREMIC SYNDROME; HUMANS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOMODULIN;

EID: 84886003503     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/ped.12165     Document Type: Article

References (14)

1. Karmali MA, Petric M, Lim C, Fleming DC, Arthus GS, Lior H,. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 1985; 151: 775-782. (Pubitemid 15094592)
2. Keir L, Coward RJ,. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr. Nephrol. 2011; 26: 523-533.
3. Karpman D, Sartz L, Johnson S,. Pathophysiology of typical hemolytic uremic syndrome. Semin. Thromb. Hemost. 2010; 36: 575-585.
4. Scheiring J, Andreoli SP, Zimmerhackl LB,. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr. Nephrol. 2008; 23: 1749-1760.
5. Bitzan M, Bickford BB, Foster GH,. Verotoxin (shiga toxin) sensitizes renal epithelial cells to increased heme toxicity: Possible implications for the hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2004; 15: 2334-2343. (Pubitemid 39159333)
6. Esmon CT,. The interactions between inflammation and coagulation. Br. J. Haematol. 2005; 131: 417-430. (Pubitemid 43899639)
7. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009; 361: 345-357.
8. Yamakawa K, Fujimi S, Mohri T, et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: A historical control study. Crit. Care 2011; 15: R123.
9. Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial. J. Thromb. Haemost. 2007; 5: 31-41. (Pubitemid 44921064)
10. Honda T, Ogata S, Mineo E, et al. A novel strategy for hemolytic uremic syndrome: Successful treatment with thrombomodulin α. Pediatrics 2013; 131: e928-933.
11. Mahan JD,. Hemolytic uremic syndrome. In:, Kher KK, Schnaper HW, Makker SP, (eds). Clinical Pediatric Nephrology, 2nd edn. Informa UK, London, 2007; 235-244.
12. Kato T, Sakai T, Kato M, et al. Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: A retrospective cohort study. Thromb J. 2013; 11: 3.
13. Levi M, van der Poll T,. Recombinant human activated protein C: Current insights into its mechanism of action. Crit. Care 2007; 11 (Suppl. 5): S3.
14. Aikawa N, Shimazaki S, Yamamoto Y, et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: Subanalysis from the phase 3 trial. Shock 2011; 35: 349-354.